Purpose. Obtaining a drug intended for the prevention and treatment of rickets and rickets-like diseases in children, D-hypovitaminosis in pregnant women, mineral metabolism disorders, osteopathies of various origins (osteomalacia, osteoporosis, orthopedic deformities, limb fractures, etc.), in complex therapy of cardio -vascular diseases, rheumatoid arthritis and other diseases
Specifications. The technology makes it possible to provide improved characteristics to the resulting therapeutic and prophylactic drug vitamin D3-E protein complex: – double protection of vitamin D3 from oxidation by the protein casein and a physiological dose of vitamin E; – increase the range of vitamin D3 content in 200 mg of the drug (1 tablet) from 1000 to 5000 IU; – high stability of the active components at room temperature, which increases the shelf life of the finished product to 5 years versus 1-2 years for other commercial vitamin D3 preparations. – high bioavailability and therapeutic effectiveness, which, according to clinical studies, is 40% higher than existing analogues of vitamin D3 preparations. The content of 25OHD3 in blood serum after taking the drug exceeds commercial analogues of vitamin D3 in the form of CWS by 1.5 times, in oil solution – by 2.4 times, and commercial analogues of vitamin D2 – by 2 times; – high bacterial purity from non-pathogenic bacteria and yeast fungi; – absence of preservatives and synthetic stabilizers
Application area. Healthcare.
Advantages. The technology is used on standard equipment to obtain a drug with unique properties: – double protection of vitamin D3 from oxidation by a protein complex and a physiological dose of vitamin E; – protection from the negative effects of gastrointestinal detergents on vitamin D3; – the content of vitamin D3 in 200 mg of the drug “VIDEIN D3-E” is from 1000 to 5000 IU; – high stability: increased shelf life of active components at room temperature (5 years versus 1-2 years for other commercial vitamin D3 preparations); – high bioavailability; – absence of preservatives and synthetic stabilizers.
Technical and economic effect. A 40% increase in bioavailability and therapeutic effectiveness with a 2-fold increase in shelf life compared to existing analogues of vitamin D preparations, as well as bacterial purity, makes it possible to reduce the costs of prevention and treatment of this pathology by 2.3 times, which has extremely powerful technical, economic and social benefits. Effect.
Description. The essence of the technology is based on obtaining a finished form of the drug vitamin D3-E protein complex, which increases the binding capacity of vitamins D3 and E with casein and the resistance of these bonds to the effects of negative factors, increasing the shelf life of vitamin D3-E containing preparations by 2 times, as well as obtaining a bacterially pure substance. An industrial technology has been created for obtaining a finished form of the vitamin D3-E protein complex preparation, which provides double protection against the oxidation of vitamin D3 in the preparation, as well as protection against the negative effects of gastrointestinal detergents. As a result, the degree of provision of the body with active metabolites increases and preventive and therapeutic effectiveness increases. The technology increases the binding capacity of vitamins D3 and E with casein, the stability of the bonds, and increases the shelf life of the drug by 2 times. The technology makes it possible to obtain an effective form of the drug vitamin D3-E protein complex with an expanded tolerance for the concentration of vitamin D3, vitamin E and the possibility of additional introduction of other fillers and diluents. The technology ensures the creation of a vitamin D3-E protein complex preparation of a combined composition that regulates the processes of metabolism, proliferation and differentiation of cells in all organs and tissues.